|1.||Peloquin, Charles A: 13 articles (08/2014 - 05/2003)|
|2.||Weiner, Marc: 12 articles (03/2015 - 08/2002)|
|3.||Nuermberger, Eric L: 12 articles (03/2015 - 12/2005)|
|4.||Grosset, Jacques H: 9 articles (08/2012 - 12/2005)|
|5.||Sterling, Timothy R: 8 articles (08/2015 - 06/2002)|
|6.||Tuberculosis Trials Consortium: 7 articles (08/2015 - 08/2002)|
|7.||Rosenthal, Ian M: 7 articles (08/2012 - 12/2005)|
|8.||Chaisson, Richard E: 6 articles (10/2015 - 04/2006)|
|9.||Vernon, Andrew: 6 articles (02/2015 - 06/2002)|
|10.||Dorman, Susan E: 6 articles (02/2015 - 11/2008)|
12/01/2005 - "To test this hypothesis we evaluated the sterilizing activity of improved once-weekly rifapentine-based continuation phase regimens in a murine model that mimics the treatment of high-risk patients with tuberculosis. "
08/01/2014 - "In this exploratory study, we characterized the free plasma fraction of rifapentine in 41 patients with tuberculosis. "
03/01/2010 - "Study 29 is currently underway, in which rifapentine was introduced in the experimental regimen for active tuberculosis treatment."
06/01/2004 - "The present pharmacokinetic study supports further trials to determine the optimal rifapentine dose for treatment of tuberculosis."
06/01/2002 - "We conducted a prospective, randomized, double-blind trial of rifapentine at three doses (600, 900, and 1,200 mg) plus INH 15 mg/kg once weekly in the continuation phase treatment of culture-positive tuberculosis in 150 human immunodeficiency virus-seronegative adults. "
03/01/2015 - "Inhaled delivery of rifapentine has the potential to selectively enhance therapeutic efficacy at the pulmonary site of infection whilst minimising systemic exposure and related toxicity. "
03/01/2014 - "Recent animal studies have shown that more frequent administration of rifapentine could shorten treatment times, for both latent and active TB infection. "
10/01/1999 - "In this study, we evaluated the ability of rifapentine (RFP), in monotherapy and combination therapy, to completely eradicate a Mycobacterium tuberculosis infection and to prevent relapse posttreatment in a Swiss mouse model. "
06/01/2014 - "Update on cost-effectiveness of a 12-dose regimen for latent tuberculous infection at new rifapentine prices."
05/01/2014 - "A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection."
01/01/2011 - "Rifapentine-based regimens for treating latent tuberculosis infection (LTBI) are being considered for future clinical trials, but even if they prove effective, high drug costs may limit their economic viability. "
06/01/2002 - "Rifapentine 900-mg, once-weekly dosing appears to be safe and well tolerated and is being evaluated in Phase III efficacy trials of treatment of latent tuberculosis. "
09/01/1999 - "In this study we measured the efficacies of rifapentine-containing intermittent drug regimens for preventive therapy using the Cornell mouse model of latent tuberculosis. "
10/01/2015 - "Rifapentine for latent tuberculosis infection treatment in the general population and human immunodeficiency virus-positive patients: summary of evidence."
06/01/2014 - "Use of higher weight-adjusted rifapentine doses for young children are warranted to achieve systemic exposures that are associated with successful treatment of latent tuberculosis infection in adults."
08/17/2002 - "Rifapentine once a week is safe and effective for treatment of pulmonary tuberculosis in HIV-negative people without cavitation on chest radiography. "
07/01/2015 - "Two-stage activity-safety study of daily rifapentine during intensive phase treatment of pulmonary tuberculosis."
05/15/2015 - "Erratum: daily rifapentine for treatment of pulmonary tuberculosis: a randomized, dose-ranging trial."
02/01/2015 - "We conducted a randomized, partially blinded dose-ranging study to determine tolerability, safety, and antimicrobial activity of daily rifapentine for pulmonary tuberculosis treatment. "
11/01/2005 - "This study was designed to describe the population pharmacokinetics of rifapentine (RFP) and 25-desacetyl RFP in a South African pulmonary tuberculosis patient population. "
01/01/1987 - "The purpose of this study was to determine the effect of rifampin and its cyclopentyl analogue, MDL 473, on delayed type hypersensitivity (DTH) using a murine model. "
01/01/1987 - "Effect of rifampin and its cyclopentyl analogue, MDL 473, on the expression of delayed type hypersensitivity to oxazolone."
03/01/2010 - "It would be of interest to profile rifalazil and analogs in relation to rifampin, rifapentine, and rifabutin in a variety of screens, particularly those that might relate to hypersensitivity or immunomodulatory processes."
|4.||1- (6- bromo- 2- methoxy- quinolin- 3- yl)- 4- dimethylamino- 2- (3- fluorophenyl)- 1- phenyl- butan- 2- ol (R207910)
|7.||polylactic acid-polyglycolic acid copolymer (PLGA)
|1.||Drug Therapy (Chemotherapy)
|3.||Directly Observed Therapy